Eleftheria Kranidioti, Isis Ricaño-Ponce, Nikolaos Antonakos, Evdoxia Kyriazopoulou, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Nikoleta Rovina, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George N Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vasilios Koulouras, Apostolos Komnos, Theano Kontopoulou, George Dimopoulos, Mihai G Netea, Vinod Kumar, Evangelos J Giamarellos-Bourboulis
{"title":"Modulation of Metabolomic Profile in Sepsis According to the State of Immune Activation.","authors":"Eleftheria Kranidioti, Isis Ricaño-Ponce, Nikolaos Antonakos, Evdoxia Kyriazopoulou, Antigone Kotsaki, Iraklis Tsangaris, Dimitra Markopoulou, Nikoleta Rovina, Eleni Antoniadou, Ioannis Koutsodimitropoulos, George N Dalekos, Glykeria Vlachogianni, Karolina Akinosoglou, Vasilios Koulouras, Apostolos Komnos, Theano Kontopoulou, George Dimopoulos, Mihai G Netea, Vinod Kumar, Evangelos J Giamarellos-Bourboulis","doi":"10.1097/CCM.0000000000006391","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the metabolomic profiles associated with different immune activation states in sepsis patients.</p><p><strong>Design: </strong>Subgroup analysis of the PROVIDE (a Personalized Randomized trial of Validation and restoration of Immune Dysfunction in severe infections and Sepsis) prospective clinical study.</p><p><strong>Setting: </strong>Results of the PROVIDE study showed that patients with sepsis may be classified into three states of immune activation: 1) macrophage-activation-like syndrome (MALS) characterized by hyperinflammation, sepsis-induced immunoparalysis, and 3) unclassified or intermediate patients without severe immune dysregulation.</p><p><strong>Patients or subjects: </strong>Two hundred ten patients from 14 clinical sites in Greece meeting the Sepsis-3 definitions with lung infection, acute cholangitis, or primary bacteremia.</p><p><strong>Interventions: </strong>During our comparison, we did not perform any intervention.</p><p><strong>Measurements and main results: </strong>Untargeted metabolomics analysis was performed on plasma samples from 210 patients (a total of 1394 products). Differential abundance analysis identified 221 significantly different metabolites across the immune states. Metabolites were enriched in pathways related to ubiquinone biosynthesis, tyrosine metabolism, and tryptophan metabolism when comparing MALS to immunoparalysis and unclassified patients. When comparing MALS to unclassified, 312 significantly different metabolites were found, and pathway analysis indicated enrichment in multiple pathways. Comparing immunoparalysis to unclassified patients revealed only two differentially regulated metabolites.</p><p><strong>Conclusions: </strong>Findings suggest distinct metabolic dysregulation patterns associated with different immune dysfunctions in sepsis: the strongest metabolic dysregulation is associated with MALS.</p>","PeriodicalId":10765,"journal":{"name":"Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":7.7000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCM.0000000000006391","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the metabolomic profiles associated with different immune activation states in sepsis patients.
Design: Subgroup analysis of the PROVIDE (a Personalized Randomized trial of Validation and restoration of Immune Dysfunction in severe infections and Sepsis) prospective clinical study.
Setting: Results of the PROVIDE study showed that patients with sepsis may be classified into three states of immune activation: 1) macrophage-activation-like syndrome (MALS) characterized by hyperinflammation, sepsis-induced immunoparalysis, and 3) unclassified or intermediate patients without severe immune dysregulation.
Patients or subjects: Two hundred ten patients from 14 clinical sites in Greece meeting the Sepsis-3 definitions with lung infection, acute cholangitis, or primary bacteremia.
Interventions: During our comparison, we did not perform any intervention.
Measurements and main results: Untargeted metabolomics analysis was performed on plasma samples from 210 patients (a total of 1394 products). Differential abundance analysis identified 221 significantly different metabolites across the immune states. Metabolites were enriched in pathways related to ubiquinone biosynthesis, tyrosine metabolism, and tryptophan metabolism when comparing MALS to immunoparalysis and unclassified patients. When comparing MALS to unclassified, 312 significantly different metabolites were found, and pathway analysis indicated enrichment in multiple pathways. Comparing immunoparalysis to unclassified patients revealed only two differentially regulated metabolites.
Conclusions: Findings suggest distinct metabolic dysregulation patterns associated with different immune dysfunctions in sepsis: the strongest metabolic dysregulation is associated with MALS.
期刊介绍：
Critical Care Medicine is the premier peer-reviewed, scientific publication in critical care medicine. Directed to those specialists who treat patients in the ICU and CCU, including chest physicians, surgeons, pediatricians, pharmacists/pharmacologists, anesthesiologists, critical care nurses, and other healthcare professionals, Critical Care Medicine covers all aspects of acute and emergency care for the critically ill or injured patient.
Each issue presents critical care practitioners with clinical breakthroughs that lead to better patient care, the latest news on promising research, and advances in equipment and techniques.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
